` ATORX (Alligator Bioscience AB) vs OMX Stockholm 30 Comparison - Alpha Spread

ATORX
vs
OMX Stockholm 30

Over the past 12 months, ATORX has underperformed OMX Stockholm 30, delivering a return of -94% compared to the OMX Stockholm 30's 5% drop.

Stocks Performance
ATORX vs OMX Stockholm 30

Loading

Performance Gap
ATORX vs OMX Stockholm 30

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
ATORX vs OMX Stockholm 30

Loading
ATORX
OMX Stockholm 30
Add Stock

Competitors Performance
Alligator Bioscience AB vs Peers

OMX Stockholm 30
ATORX
ABBV
AMGN
GILD
VRTX
Add Stock

Alligator Bioscience AB
Glance View

Market Cap
85.7m SEK
Industry
Biotechnology

Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.

ATORX Intrinsic Value
Not Available
Back to Top